Alvotech Ordinary Shares

ALVO

NASDAQ. Currency in USD

6.83 +0.09 ( +1.38% )

Real time prices: September 23

Market Cap.
1.70B
Beta (5Y monthly)
-
Price/Earnings
973.13
EPS (TTM)
0.01
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
50,125
1y Target Est.
13.60
Day's Range
6.61
-
7.30
52 Week's Range
5.20
-
14.04

Historical Summary

Performance
Share Buybacks

About Alvotech Ordinary Shares

Sector
Unknown
Industry
Unknown
Website
https://www.alvotech.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
0
Employees
784
Address
Saemundargata 15-19, Reykjavik, Iceland, 102
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Latest news

Alvotech Reports Update on Initial AVT02 Biologics License Application
Alvotech Reports Update on Initial AVT02 Biologics License Application

REYKJAVIK, Iceland, Sept. 05, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company...
By GlobeNewswire Inc. - 2 weeks ago

Alvotech Reports First Half 2022 Financial Results and Business Update
Alvotech Reports First Half 2022 Financial Results and Business Update

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and...
By GlobeNewswire Inc. - 3 weeks ago

Alvotech leggur áherslu á sjálfbærni og samfélagslega ábyrgð og birtir upplýsingar fyrir árin 2020 og 2021
Alvotech leggur áherslu á sjálfbærni og samfélagslega ábyrgð og birtir upplýsingar fyrir árin 2020 og 2021

Alvotech kynnti í dag að fyrirtækið hefði birt upplýsingar um mælikvarða á frammistöðu í umhverfismálum,...
By GlobeNewswire Inc. - 3 weeks ago

Alvotech hefur klíníska rannsókn á AVT03, fyrirhugaðri líftæknilyfjahliðstæðu við Prolia® og Xgeva®
Alvotech hefur klíníska rannsókn á AVT03, fyrirhugaðri líftæknilyfjahliðstæðu við Prolia® og Xgeva®

Alvotech (NASDAQ og First North Growth: ALVO) hefur hafið klíníska rannsókn á AVT03 (denosumab), fyrirhugaðri...
By GlobeNewswire Inc. - 4 weeks ago

Alvotech to Participate in Two Upcoming Investor Conferences in September 2022
Alvotech to Participate in Two Upcoming Investor Conferences in September 2022

REYKJAVIK, Iceland and NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a...
By GlobeNewswire Inc. - 4 weeks ago